Abstract A conceptual model framework and an initial literature review are invaluable when considering what health state utility values (HSUVs) are required to populate health states in decision models. They are the recommended starting point early within a research and development programme, and before development of phase III trial protocols. While clinical trials can provide an opportunity to collect the required evidence, their appropriateness should be reviewed against the requirements of the model structure taking into account population characteristics, time horizon and frequency of clinical events. Alternative sources such as observational studies or registries may be more appropriate when evidence describing changes in HSUVs over time or rare clinical events is required. Phase IV clinical studies may provide the opportunity to collect additional longitudinal real-world evidence. Aspects to consider when designing the collection of the evidence include patient and investigator burden, whom to ask, the representativeness of the population, the exact definitions of health states within the economic model, the timing of data collection, sample size, and mode of administration. Missing data can be an issue, particularly in longitudinal studies, and it is important to determine whether the missing data will bias inferences from analyses. For example, respondents may fail to complete followup questionnaires because of a relapse or the severity of their condition. The decision on the preferred study type and the particular quality of life measure should be informed by any evidence currently available in the literature, the design of data collection, and the exact requirements of the model that will be used to support resource allocation decisions (e.g. reimbursement).
Introduction
When considering health state utility evidence for use in decision models, the recommended starting point is early within a research and development (R&D) programme and before the development of any trial protocol [1] . An initial literature review is essential to determine whether the & John Brazier j.e.brazier@sheffield.ac.uk required health state utility values (HSUVs) are currently available or whether new evidence is required [2, 3] . A conceptual model framework can help to identify the requirements of the decision analytic model (DAM), and a modeller should be consulted to determine the requirements prior to conducting the literature review or designing protocols for any associated clinical trials or observational studies [1] . However, DAMs regularly evolve over time, and it is possible that the full requirements will not be known until the final health states have been agreed. Consequently, while an early or conceptual model can inform trial protocols, the final DAM is more useful when examining the literature. This article covers the advantages and disadvantages of collecting preference-based measures and other health-related quality-of-life (HRQoL) measures to generate HSUVs in alternative study designs [e.g. randomised controlled trials (RCTs), observational studies, registries], considerations when designing the collection of evidence (e.g. relevance of the population, timing of collection, mode of administration), and recommendations for data analysis and reporting standards. The focus is the use of clinical studies to collect HSUVs for use in DAMs designed to compare the long-term benefits of alternative interventions (as opposed to economic evaluations conducted alongside short-term clinical trials).
Alternative Sources of Evidence for Health State Utility Values (HSUVs)
Numerous forms of study design can be used to collect HSUV evidence, including clinical trials (defined as RCTs comparing the efficacy of interventions), observational studies [e.g. cross-sectional (collect evidence at one point in time) or longitudinal (collect repeated observations of the same variable over periods of time)], registries (generally longitudinal, and collect specified outcomes from a particular population generally defined by a specific condition such as cancer or cardiovascular disease). There is also the option of vignette studies, bespoke studies designed to elicit preferences for a small number of predefined health states (see [4] for more discussion on this approach).
Clinical Trials
Clinical trials can provide important and useful means to collect the required HSUVs. Their use preserves and enhances internal validity as the benefits (clinical effect and HSUVs) of the interventions are collected within the same study and the HSUVs are collected directly from recipients of the intervention(s) under appraisal. This has the additional benefit of enabling measurement of the impact of side effects of the interventions. However, there are numerous limitations, such as the representativeness of the study population, the enhanced medical care provided, the sample size, the time horizon of the trial, and potential implications for regulatory approval.
Representativeness of the Study Population
Strict exclusion criteria [such as exclusion of younger or older age groups; certain disease severities; or people with comorbidities, receiving non-study medications, with a recent history of related clinical events (e.g. immediately post stroke) or at the extremes of the disease spectrum] can mean that the trial population may not be fully representative of the target population in clinical practice. While adjustments may be made using prognostic models to account for some of these factors, this would introduce an additional level of uncertainty and is less credible than collecting evidence on the full range of individuals of interest.
Enhanced Medical Care
Clinical protocols may involve high levels of monitoring and follow-up and investigational procedures not generally observed in routine clinical practice. It is possible that the levels of healthcare provided may increase recipients' sense of well-being and potentially HRQoL, thus decreasing confidence in generalisability to patients in routine clinical practice.
Trial Time Horizon
Clinical trials tend to use relatively short time horizons, whereas DAMs frequently need the lifetime health benefits and costs associated with interventions. Consequently, HSUVs collected in clinical trials may not be suitable for all health states within the DAM and are generally not useful for longer-term evidence (e.g. how HSUVs change over time after fractures) or specific clinical events as trials are designed to compare arms rather than the effect associated with clinical events. The time horizon also has implications when HSUVs are required for rarer, less frequent events as these may not be observed within the short time horizon of the clinical trial. Alternative or additional sources such as registries or observational studies may provide more appropriate evidence in these instances.
Sample Size
Study sample size for experimental studies is generally calculated to detect a difference (or equivalence) in clinical effect rather than HRQoL. Consequently, when subgrouping by clinical event type (e.g. fracture site in osteoarthritis trials), the number of patients within the trial who experience a specific event may be too small to detect a statistically significant difference in HSUVs. While this may not be strictly necessary for an economic model, smaller samples will increase the uncertainty in results. In addition, if the data are analysed by event type and treatment arm, any observed difference in mean HSUV may not be detected as statistically significant as the difference is too subtle to detect; these differences may be further affected by factors such as missing data, cross-over and loss to follow-up (see example in Box 1).
Implications for Regulatory Approval
The use of generic preference-based measures (GPBMs) to collect HSUVs in trials can be misleading where they have been powered on different endpoints [5] . This carries a risk: if the US FDA/European Medicines Agency (EMA) review the evidence and the results are not statistically significant or are inconsistent with other patient-reported outcome measures, this may affect the chances of approval. The value of patient-reported outcome data to the intervention under appraisal should be assessed to determine whether it is likely to be a key differentiator. The GPBM should be examined to determine whether it could capture the treatment effect in a given population. One way around this would be to include the preference-based measure as an exploratory endpoint and only include descriptive data (e.g. responses to the health dimensions) in the statistical analysis plan, as opposed to using the traditional approach of comparison between treatment arms. Depending on the HSUVs required to satisfy the DAM, one alternative could be to limit the collection of the GPBM to the baseline and clinical events (e.g. immediately post hip fractures) only, as opposed to end of follow-up. One could also argue that comparison across the trial arms could be misleading due to censoring and loss to follow-up, among others.
Observational Studies
There are numerous reasons why observational studies may be preferred over clinical trials, including the arguments that evidence from clinical trials is not representative of general clinical practice because of the exacting inclusion and exclusion criteria, the more intensive care provided to participants, the time horizon and the regimented timing of data collection. Bespoke observational studies can provide extremely important 'real-world' utility evidence and can range from simple online surveys to complex longitudinal surveys with repeated measures collected over time. Observational study designs can be cross-sectional (collect evidence at one point in time) or longitudinal (collect repeated observations of the same variable over periods of time).
Longitudinal studies can be designed to examine the immediate and long-term effects associated with discrete events (such as the acute period after a fracture or the longer term after rehabilitation), or they can collect changes over time associated with chronic progressive conditions such as rheumatoid arthritis or Crohn's disease. Prospective cohort studies (a sub-type of longitudinal studies) can be designed to target a particular subgroup of patients matching the characteristics required for rare health states or clinical events. The main disadvantages of prospective studies are the resource (both cost and time) implications involved in identifying and recruiting the required sample.
Cross-sectional surveys provide evidence collected at one point in time and thus may include difficulties in matching evidence of HRQoL with precisely defined health states. For example, a myocardial infarction could be defined as the immediate period following the acute clinical event or as later periods such as 6 months, 12 months or 5 years after the event. While it is possible to subgroup by time since event in these cases, a much larger sample size is required. However, compared with longitudinal studies, they are a relatively quick and inexpensive source of evidence.
In addition to the costs of conducting a bespoke study, there can be problems with recruitment (e.g. when the participants' characteristics are to match some pre-defined clinical definition such as severity or history of events) and retention (particularly when conducting longitudinal studies). Patients' medical history (i.e. current or previous
Box 1 Example from the UKPDS [6]
The landmark UK Prospective Diabetes Study (UKPDS) of glycaemic therapies in patients with newly diagnosed type 2 diabetes demonstrated that intensive blood glucose control significantly reduced the long-term sequelae (micro and macrovascular complications) of diabetes.
While no difference in EQ-5D evidence (n = 3667) was observed across treatment arms when using conventional significance levels, subsequent analyses subgrouped long-term clinical outcomes (myocardial infarction, ischaemic heart disease, stroke, heart failure, amputation and visual acuity) and clearly demonstrated a significant detrimental effect on HSUVs associated with the events [6, 7] . health conditions) may be self-reported, which is not always considered reliable [8] .
Registries
Registries can provide an alternative source of evidence [9] [10] [11] [12] [13] . The benefits are the comparatively low costs associated with obtaining the data (if owned by a second party), and they may also include patients eligible for the intervention in clinical practice who are excluded from the clinical trials. However, when using existing datasets designed to satisfy other research questions, there may be problems in matching the requirements of the DAM with the data available.
Reviews of the Literature
Some health technology assessment (HTA) agencies [e.g. the National Institute for Health and Care Excellence (NICE)] [14] require a literature review, and the results can be informative in terms of both the measure to be used to collect the HSUVs and the range of estimates that should be explored in economic sensitivity analyses [15] .
Supplementary Evidence
Finally, consideration should be given to including preference-based measures in phase IV studies. These studies may include real-world evidence used in clinical practice and tend to be longer in duration than phase III. They may use less stringent inclusion/exclusion criteria and thus provide greater opportunities to obtain the evidence required for re-assessment and future reimbursement submissions; this evidence can be compared with and support the evidence collected in the earlier clinical trials.
What to Consider When Designing the Collection of Data
A range of issues should be considered when designing the collection of HSUVs, irrespective of the study design or measure selected. These include matching the definitions of the anticipated health states/events in the early economic model, whom to ask, the representativeness of the study population, the timing of assessments, repeated measures, mode of administration, sample size, and patient and investigator burden.
Whom to Ask
It is common practice to obtain health status descriptions directly from patients as they are generally in the best position to know how their health has affected their function and well-being [16, 17] . Responses from proxies (e.g. family member, principle carer, clinician, etc.) are not always directly comparable with those obtained from patients, regardless of the measure used (see example in Box 2) [18, 19] . Consequently, if used in a DAM, this potential bias should be acknowledged in the text and a series of sensitivity analyses conducted to illustrate the effect of the uncertainty in this evidence. However, there are instances when it is not possible to ask patients to rate their own health, such as when patients have severe mental health conditions or are too ill or too young. In these cases, responses from proxies may be used, but it is recommended that patient responses are used when they are willing and able to provide this evidence [14, 17] . An additional consideration is involved where there is a significant impact on the informal carer(s), such as with dementia or Parkinson's disease [21] . To measure the full impact of an intervention, it will be necessary to collect HRQoL data from the carer as well as from the person for whom they care and is receiving the intervention.
Representativeness of the Study Population
The study participants should reflect the population in the DAM, i.e. patients who would receive the intervention under appraisal if it was provided in routine clinical practice. In many cases, if a particular subgroup in the DAM has been excluded from the clinical trial, evidence from observational studies may be preferable as these studies may be designed to recruit patients with pre-defined characteristics from the target population.
Box 2 Patient versus proxy measurement of health-related quality of life in dementia EQ-5D Patients' carers reported higher levels of disability than did the patients across all five dimensions on the EQ-5D in a study of patients with dementia [19] . Conversely, clinicians reported fewer problems on the dimensions 'pain/discomfort' and 'anxiety/depression'. The level of agreement between responses was assessed as only fair.
ICECAP Work experience and gender were reported to influence proxy responses to the ICEpop CAPability Measure for Older People (ICECAP-O) when used to assess well-being in older patients with dementia residing in a nursing home [20] .
Fit the Decision Problem: The Definitions of Health States Within the Decision Analytic Model
Care should be taken to ensure the characteristics of the target population cover the full range of definitions (health states, events) of health states within the early DAM. This is particularly relevant for progressive conditions (e.g. arthritis or Parkinson's disease where patients at the more severe end of the disease spectrum may be less likely to respond) or when evidence from relatively rare events or complications is needed. In the latter instance, a prospective study targeting a specific subgroup more likely to experience the event may be considered. However, response rates are likely to be extremely poor in patients experiencing serious adverse events or approaching end of life in palliative care [1] . In these cases, evidence from proxies should be considered (see Sect. 3.1).
Timing of Data Collection
Assessments in clinical trials are generally at scheduled intervals such as when administering the intervention at out-patient appointments (e.g. 1 week, 4 weeks, 12 weeks). These time points may not coincide with the timing necessary to capture the effects of interventions and clinical endpoints required for the DAM such as symptom flares or hospitalisations. For example, HSUVs in cancer trials are generally collected during visits for chemotherapy (approximately every 3 weeks), but these are unlikely to capture the effects of chemotherapy toxicity that generally occur between treatments, and start just after disease progression or the end-of-life period. Similarly, inflammatory conditions are characterised by flares in symptoms, and it could be difficult to capture the HSUVs associated with these if the scheduled intervals are adhered to. The schedule for collection of utility data should be flexible to enable the capture of changes associated with such flares (or discrete clinical events) and should be synchronised with the collection of condition-specific measures. For DAMS where the clinical variable used to describe the effectiveness of an intervention is used to represent progression over time, such as arthritis [uses the Health Assessment Questionnaire (HAQ)] or ankylosing spondylitis [uses the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI)], it is important to ensure the clinical variable is collected at the same time point as the evidence for the HSUV. Models used to evaluate interventions in these types of chronic progressive conditions tend to use a mapping function that describes the relationship between the clinical variable and the HSUV to interpolate and extrapolate the required HSUVs across the full disease spectrum [22] .
DAMs frequently use a lifetime horizon and-depending on the condition of interest-may require HSUVs that change over time, such as in progressive conditions. As evidence is rarely collected in clinical trials for a sufficient length of time, analysts have historically sourced this form of evidence from cross-sectional studies because this is less expensive and easier to collect (due to problems with nonresponse/retention) than evidence from repeated-measure studies. However, evidence suggests that cross-sectional data may provide biased estimates of the effects on HRQoL because differences in observed quality of life between patients with and without an event may be due to underlying heterogeneity across the two types of patients rather than to the event [7] . This bias is introduced because crosssectional analyses attribute all observed differences in quality of life between patients with and without an event to the event, when in reality some or all of the difference may be due to underlying heterogeneity across the two types of patients rather than the event.
Conversely, missing data is common in longitudinal data and can be extremely problematic because of the nonrandom nature of drop-outs. This can contribute to bias if the missing data are systematically different from the observed evidence [23] .
In addition to matching the requirements of the DAM, when scheduling the timing of data collection, the recall period of the measure should be considered. For example, the EuroQol 5-Dimensions (EQ-5D) asks respondents to value their health today, whereas the 36-Item Short-Form Health Survey (SF-36) and SF-12 use recall periods of 4 weeks and 1 week (acute version) [24, 25] . As such, the recall period of the EQ-5D may be more appropriate than that of the SF-36 in an efficacy study of clopidogrel in patients undergoing a cardiac stenting procedure when the HSUVs for the DAM are required for the days immediately after surgery. Conversely, if the evidence-collection points are pre-scheduled to match clinical appointments in an efficacy study, the recall period of the SF-36 may be more appropriate than that of the EQ-5D in conditions characterised by flares, as the probability of having a flare on the pre-scheduled day is smaller than the probability of having a flare between visits.
Sample Size
As the objective is to collect HSUVs for use in DAMs, the sample size should be governed by the need for precision (and uncertainty) in the HSUVs rather than statistical comparisons between arms within the study. If subgroup analyses are to be conducted (e.g. examining differences in HSUVs for numerous discrete clinical events such as in a cardiovascular disease study), this should be considered in the sample size calculation. In DAMs sensitive to the HSUVs, the sample size required to reduce uncertainty around the point estimate may be calculated using valueof-information techniques, otherwise standard techniques using confidence intervals [17] . Value-of-information techniques consider the uncertainty surrounding the current evidence and the implications of reducing the uncertainty around the incremental cost-effectiveness ratio for a given threshold in a DAM and thus the added value to a decision maker (in this case through increasing the sample size for the HSUVs) [17] .
Mode of Administration
The vast majority of HRQoL measures, such as GPBMs, are designed as self-administered questionnaires to be completed using pen/paper, online or via tablets and smartphones. The main advantages of self-completion are the relatively low cost and increasing the probability of acquiring responses to sensitive questions. The main disadvantages are the low response rates and the difficulties in obtaining a truly accurate sample representative of the full target population, which may introduce responder bias (where respondents differ from non-respondents in terms of socio-demographic and other characteristics). Electronic versions are now available for all the main GPBMs, and a recent study comparing evidence on the EQ-5D-5L collected using either paper or a mobile phone application reported equivalent results and response rates [26, 27] .
Evidence can also be collected using interviews where the interviewer rather than the respondent records the responses. Face-to-face interviews tend to be used where additional and often complex information is required above the evidence on HRQoL. Although face-to-face interviews are an expensive method of collecting evidence and introduce another potential source of bias (from the interviewer), response rates are typically higher than for postal surveys, and-as information is obtained from target respondents-sample composition bias is generally reduced. Telephone interviews are a relatively quick and low-cost alternative to face-to-face methods, but response rates tend to be lower. The advantage over face-to-face interviews is that interviewer bias can be reduced through close supervision, and a more accurate assessment is obtained when patients are at home rather than in the clinic [28] . The disadvantage is that respondents may find complex questions difficult to answer, the risk of interviewer bias remains, and-while the cost is still lower than for face-to-face interviews-it is still higher than web-based collection. Some evidence suggests that the mode of administration can affect responses, for example, respondents may be more likely to report the highest or the lowest categories when responding to a verbal rather than a written self-report health questionnaire [29] .
Given differences attributable to administration mode and who administers the questionnaire, such as sample representativeness, response rates, comprehension and response strategies, it has been suggested that the mode of administration be standardised (i.e. that only one mode of administration be used within a study) [1] . However, choice depends on factors such as the characteristics of the target population (e.g. response rates could be low when using electronic versions in elderly populations) and time or resource constraints, and the ultimate decision depends on the relevance of the administration mode to the individual study. If more than one mode of administration is required to optimise the flexibility and thus response rates (e.g. in rare conditions), the collection mode could be used as a covariate in subsequent analyses and the modes of collection agreed a priori.
Patient and Investigator Burden
The inclusion of a GPBM or other HRQoL measure in a clinical trial is commonly objected to on the grounds of the additional burden placed on the patient and investigator [30] . This can be particularly relevant when frequent assessments are required to satisfy the needs of the DAM. The requirements of the differing authorities should be balanced and the importance of high-quality evidence on HSUVs to reimbursement authorities should be considered, particularly when it is necessary to synchronise data collection timing with clinical variables or tests.
Some measures (e.g. the EQ-5D) take minutes to complete, whereas others can be more burdensome [31, 32] . Ultimately HSUVs should be collected using a measure that is appropriate in the health condition of interest and satisfies the relevant reimbursement authority [33] . If the psychometric properties of the required measure have not been assessed in the target population, inclusion in phase II studies could provide an opportunity to address this.
Recommendations for Developing an HSUV Research Plan
To ensure appropriate HSUV evidence is available when needed, it is important to develop and document an early HSUV research plan/strategy (see Fig. 1 ). An early understanding of the exact requirements of the DAM and continued input from an experienced healthcare modeller is essential at all stages. The strategy for collection of HSUVs should be developed in conjunction with the intervention's R&D programme and should be informed by a literature review and-at the very least-an early conceptual economic model during phase I and II clinical studies. The conceptual model, an often overlooked stage in R&D plans, will assist in the development process of the actual DAM and will help identify the HSUV evidence needed.
Ideally, a protocol DAM should also be constructed very early on (during phase II clinical studies). Phase IV studies may provide the opportunity to collect additional longitudinal real-world evidence to supplement and compare with the existing evidence and can be used to support reassessment and re-submissions at later dates.
Recommendations for Data Analysis
The statistical analysis plan should not be constrained by the traditional approach used when analysing data for regulatory purposes (i.e. comparison between treatment arms) but should satisfy the needs of the economic analysis [1] . Country-specific preference-weights/tariffs relevant to the DAM should be applied to data from all countries for multinational studies. A recent systematic review of economic evaluations alongside multinational studies showed that methods of analysis were inconsistent between studies [34] . However, country covariates, derived from statistical regression models such as multi-level models, in order to allow for clustering, may be used to adjust for any differences in HRQoL for multinational studies. The value of the evidence to future economic evaluations may be maximised through the inclusion of prognostic factors as covariates in statistical modelling to enable the results from a clinical study to be adjusted to reflect the characteristics of populations in routine clinical practice. If statistical regression models are generated and the results used to predict the HSUVs in a DAM, the associated covariance should be reported to enable the integrity of the ordering of the HSUVs to be retained under conditions of uncertainty [35] .
Missing data can be problematic for HRQoL evidence as patients may be assessed at several time points. If data are missing, it is important to establish the level of missing data and the type of missingness. Data may be missing completely at random, missing at random, or missing not at random, also known as non-ignorable missingness [36] . Understanding why data are missing is important for HRQoL evidence, particularly if the population are severely ill, as a proportion of respondents may fail to complete the measure because of the severity of their Adapted from Wolowacz et al. [1] . CSPBM condition-specific preference-based measure, DAM decision allocation model, GPBM generic preference-based measure, HRQoL health-related quality of life, HSUV health state utility value, PBM preference-based measure condition (or death). These missing data are non-ignorable as they are directly dependent on the health status of the patient, and in these cases it is inappropriate to analyse the data using complete cases only (i.e. dropping respondents with missing data from the analyses). Methods used to handle missing data range from simple approaches, whereby patients whose data are incomplete are deleted, to more complex approaches, such as multiple imputation [37] , where missing data points are imputed in some way. The former is advantageous in terms of simplicity and ease of analyses but-in some cases-the sample size can reduce substantially, losing statistical power, and the variance in the estimates can be underestimated [38] . Not all the information is used, and, unless the data are missing completely at random, the results are likely to be biased. The main imputation methods include single imputation (mean/mode substitution, dummy variable method, single regression), which can still underestimate the variance (see for example, Briggs, Rubin, Schafler), and model-based methods (maximum likelihood, multiple imputation) [37] [38] [39] . These methods work well if data are either missing at random or missing completely at random; if data are missing not at random, then methods such as selection models and pattern mixture models should be used as they allow for systematic missingness (see, for example [39] ). A review of methods used to handle missing data in economic evaluations conducted alongside clinical trials reported that complete case analysis was the most common methodology, and frequency had increased over time despite the introduction of more sophisticated methods [40] .
Recommendations for Reporting
The foremost recommendation on reporting standards for evidence on HSUVs is transparency and justification from the initial choice of source of evidence through to the presentation of results. Any reviews conducted to inform the collection of additional evidence should be duly reported [15] . In addition to the usual information on study design, sample size, and summary variables describing the study population (age, sex, health status, etc.), it is important to provide information on the full range of the variables used within the analyses. This will allow reviewers to assess the relevance of the data in terms of where it will be used. The evidence should be compared directly with the characteristics of the patients within the DAM. Any subgroup analysis such as age or disease severity should be clearly explained together with the size.
Summary
While clinical trials can provide an efficient method of collecting the required HSUVs, observational studies provide a useful alternative when it is not possible (or desirable) to collect the HSUVs in clinical trials. The decision on the preferred study type and the preference-based measure should be informed by any evidence currently available in the literature, the design of data collection, and the exact requirements of the DAM that will be used to support reimbursement.
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